Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Palomid 529

🥰Excellent
Catalog No. T2706Cas No. 914913-88-5
Alias SG 00529, P529

Palomid 529 (SG 00529) has been used in trials studying the treatment of Age-Related Macular Degeneration.

Palomid 529

Palomid 529

🥰Excellent
Purity: 99.03%
Catalog No. T2706Alias SG 00529, P529Cas No. 914913-88-5
Palomid 529 (SG 00529) has been used in trials studying the treatment of Age-Related Macular Degeneration.
Pack SizePriceAvailabilityQuantity
5 mg$40In Stock
10 mg$64In Stock
25 mg$123In Stock
50 mg$198In Stock
100 mg$297In Stock
1 mL x 10 mM (in DMSO)$44In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Palomid 529"

Select Batch
Purity:99.03%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Palomid 529 (SG 00529) has been used in trials studying the treatment of Age-Related Macular Degeneration.
In vitro
Palomid 529 effectively inhibits tumor growth, angiogenesis, and vascular permeability. In the rabbit retinal detachment model, it significantly suppresses the proliferation of Müller cells, the formation of neuroglial scars, and photoreceptor cell death. Additionally, Palomid 529 dose-dependently inhibits Ad-VEGF-A-driven angiogenesis and, when administered orally to nude mice, restrains the growth of C6V10 gliomas. Compared to the control group, treatment with Palomid 529 in PC-3 tumor-bearing mice results in a 57.1% reduction in tumor growth. It also markedly suppresses tumor growth in mouse models of Brca1 deficiency by inhibiting the Akt and mTOR signaling pathways.
In vivo
Palomid 529 not only reduces the proliferation of ischemic retina but also improves the tissue and structure of vasculogenesis. It inhibits endothelial cell proliferation mediated by VEGF and bFGF, with IC50 values of 20 nM and 30 nM, respectively. Additionally, Palomid 529 induces apoptosis in endothelial cells and reduces the phosphorylation of pAktS473, pGSK3βS9, and pS6 induced by the vascular endothelial growth factor VEGF-A. In the lung cancer NCI-60 cell line, Palomid 529 exhibits potent antiproliferative activity, with a GI50< 35 μM. Furthermore, it significantly enhances the antiproliferative effect of radiation on prostate cancer cells (PC-3), demonstrating concentration-dependent growth inhibition in PC-3 cells. Palomid 529 inhibits radiation-induced p-Akt activation and reduces the Bcl-2/Bax ratio in PC-3 cells.
Kinase Assay
Estrogen receptor binding assays: The proteins are produced with rabbit reticulocyte lysates. The amount of template used in each reaction is determined empirically and expression is monitored in parallel reactions where [35S]methionine is incorporated into the receptor followed by gel electrophoresis and exposure to film. Binding reactions of the estrogen receptors (ER) and Palomid 529 are carried out in 100 mL final volumes in TEG buffer [10 mM Tris (pH 7.5), 1.5 mM EDTA, 10% glycerol]. In vitro transcribed-translated receptor (5 μL) is used in each binding reaction in the presence of 0.5 nM [3H]estradiol (E2). Palomid 529 is routinely tested from 10?11 to 10?6 M and diluted in ethanol. The reactions are incubated at 4 °C overnight and bound E2 is quantified by adding 200 mL dextran-coated charcoal. After a 15-minutes rotation at 4 °C, the tubes are centrifuged for 10 minutes and 150 mL of the supernatant are added to 5 mL scintillation mixture for determination of cpm by liquid scintillation counting. The maximum binding is determined by competing bound E2 with only the ethanol vehicle. Controls for background are included in each experiment using 5 mL unprogrammed rabbit reticulocyte lysate. This value, typically 10% to 15% of the maximal counts, is subtracted from all values. The data are plotted and Ki values are calculated. Experiments are conducted at least thrice in duplicate.
Cell Research
Human umbilical vascular endothelial cells (HUVEC) are used. The proliferation assay is carried out by seeding the HUVECs in 96-well plates at a density of 1,000 per well in complete medium. Following a 24-hour plating period, the cells are starved for 24 hours in 0.5% serum before being treated with Palomid 529 in the presence of 10 ng/mL basic fibroblast growth factor (bFGF) or VEGF in complete medium. After 48 hours, cell number is determined using a colorimetric method. The results are expressed as the percentage of the maximal bFGF or VEGF response in the absence of Palomid 529. Nonproliferating endothelial cells are assayed by growing HUVECs to quiescence in 96-well plates and treating with Palomid 529 for 48 hours. Initially, 5,000 cells per well are seeded and confluence is achieved the next day. The plates are incubated for another 24 hours to ensure growth arrest before treatment with Palomid 529. (Only for Reference)
AliasSG 00529, P529
Chemical Properties
Molecular Weight406.43
FormulaC24H22O6
Cas No.914913-88-5
SmilesCOc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1
Relative Density.1.280 g/cm3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 50 mg/mL (123.02 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4604 mL12.3022 mL24.6045 mL123.0224 mL
5 mM0.4921 mL2.4604 mL4.9209 mL24.6045 mL
10 mM0.2460 mL1.2302 mL2.4604 mL12.3022 mL
20 mM0.1230 mL0.6151 mL1.2302 mL6.1511 mL
50 mM0.0492 mL0.2460 mL0.4921 mL2.4604 mL
100 mM0.0246 mL0.1230 mL0.2460 mL1.2302 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Palomid 529 | purchase Palomid 529 | Palomid 529 cost | order Palomid 529 | Palomid 529 chemical structure | Palomid 529 in vivo | Palomid 529 in vitro | Palomid 529 formula | Palomid 529 molecular weight